i-SENS Showcasing Point-of-Care Diagnostics and Glucose Monitoring
Posted on 16 Nov 2026
i-SENS (Seoul, South Korea) showcases its in vitro diagnostic (IVD) systems and diabetes management technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The company presents a range of point-of-care analyzers, continuous glucose monitoring (CGM) systems, and connected diabetes care solutions designed to support diagnostic testing across hospital laboratories and near-patient settings.
Among the products on display are the i-SmartCare 10 blood gas analyzer and i-Smart 30 Pro electrolyte analyzer. These systems are designed to support clinical testing in healthcare environments where timely diagnostic results are important. The company also presents additional point-of-care analyzers, highlighting its broader portfolio of diagnostic technologies for decentralized testing.
The i-SmartCare 10 provides blood gas analysis for clinical applications, while the i-Smart 30 Pro supports electrolyte testing. Both instruments form part of i-SENS' IVD portfolio, which also includes clinical chemistry and immunoassay analyzers. The systems are intended to address diagnostic requirements across different clinical settings, from centralized laboratories to locations closer to patients.
In addition to its laboratory diagnostics portfolio, i-SENS features CareSens Air 2, its next-generation continuous glucose monitoring system. The company also displays the existing CareSens Air platform, which provides real-time glucose measurements and trend information to support diabetes management. These technologies are designed to help users monitor glucose levels and track changes over time.
The diabetes care portfolio also includes Sens365, a digital platform for glucose data management and sharing. The system enables glucose monitoring information to be organized and accessed by healthcare providers, supporting ongoing diabetes management. Visitors can also explore the company's range of CareSens blood glucose monitoring systems for routine testing.
The exhibition highlights i-SENS' focus on integrating diagnostic testing with digital health technologies. By combining point-of-care analyzers, continuous glucose monitoring, and data management platforms, the company aims to support more connected diagnostic workflows and improve access to clinical information across different healthcare environments.
i-SENS exhibits at Booth B51 in Hall 3, where visitors can examine its diagnostic and diabetes care technologies and discuss potential collaborations. The company uses its participation at MEDICA 2026 to engage with healthcare professionals and distribution partners as it continues to expand its international diagnostics business.